Redeye: Ascelia Pharma - Time for take-off
Ascelia’s Q1 result was minor compared to the recent SPARKLE success. Ascelia is preparing for submission by mid-2025, and Ascelia’s cost base was contained. Our Base Case is SEK 17 (Bull SEK 45 and Bear SEK 6).
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/